From discovery to licensure, the Adjuvant System story

References

• Gross CP, Sepkowitz KA. The myth of the medical breakthrough: smallpox, vaccination, and Jenner reconsidered. Int J Infect Dis 1998; 3:54-60; PMID:9831677; http://dx.doi.org/10.1016/S1201-9712(98)90096-0
   PubMedGoogle Scholar
• Vogel F, Hem SL. Immunologic adjuvants. In: Vaccines. Philadelphia, PA: Saunders Elsevier; 2004. page 69-79.
   Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9:287-93; PMID:19247370; http://dx.doi.org/10.1038/nri2510
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Fox CB. New generation adjuvants–from empiricism to rational design. Vaccine 2015; 33(Suppl 2):B14-20; http://dx.doi.org/10.1016/j.vaccine.2015.01.088
   PubMed Web of Science ®Google Scholar
• McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010; 33:542-54; PMID:21029964; http://dx.doi.org/10.1016/j.immuni.2010.09.011
   PubMed Web of Science ®Google Scholar
• McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 1995; 6:375-85; PMID:8938276; http://dx.doi.org/10.1016/1044-579X(95)90007-1
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5:505-17; PMID:17558426; http://dx.doi.org/10.1038/nrmicro1681
   PubMed Web of Science ®Google Scholar
• Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2010; 667:111-23; PMID:20665204; http://dx.doi.org/10.1007/978-1-4419-1603-7_10
   PubMed Web of Science ®Google Scholar
• Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012; 11:349-66; http://dx.doi.org/10.1586/erv.11.192
   PubMed Web of Science ®Google Scholar
• Ferreira MU, da Silva Nunes M, Wunderlich G. Antigenic diversity and immune evasion by malaria parasites. Clin Diagn Lab Immunol 2004; 11:987-95; PMID:15539495
   PubMedGoogle Scholar
• Morrot A, Rodrigues MM. Tissue signatures influence the activation of intrahepatic CD8(+) T cells against malaria sporozoites. Front Microbiol 2014; 5:440; PMID:25202304; http://dx.doi.org/10.3389/fmicb.2014.00440
   PubMed Web of Science ®Google Scholar
• Kaslow DC, Biernaux S. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap. Vaccine 2015; 33:7425-32; PMID:26431982; http://dx.doi.org/10.1016/j.vaccine.2015.09.061
   PubMed Web of Science ®Google Scholar
• Ballou WR, Cahill CP. Two decades of commitment to malaria vaccine development: GlaxoSmithKline Biologicals. Am J Trop Med Hyg 2007; 77:289-95; PMID:18165505
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997; 336:86-91; PMID:8988885; http://dx.doi.org/10.1056/NEJM199701093360202
   PubMed Web of Science ®Google Scholar
• Garçon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003; 2:231-8; http://dx.doi.org/10.1586/14760584.2.2.231
   PubMedGoogle Scholar
• Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE, Heppner DG, Krzych U. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol Baltim Md 1950 2003; 171:6961-7.
   Google Scholar
• Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:1927-34; PMID:11747915; http://dx.doi.org/10.1016/S0140-6736(01)06957-4
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364:1411-20; PMID:15488216; http://dx.doi.org/10.1016/S0140-6736(04)17223-1
   PubMed Web of Science ®Google Scholar
• Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, Manaca MN, Lafuente S, Barbosa A, Leach A, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007; 370:1543-51; PMID:17949807; http://dx.doi.org/10.1016/S0140-6736(07)61542-6
   PubMed Web of Science ®Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39; http://dx.doi.org/10.1586/14760584.6.5.723
   PubMed Web of Science ®Google Scholar
• Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10:471-86; http://dx.doi.org/10.1586/erv.11.29
   PubMed Web of Science ®Google Scholar
• Mettens P, Dubois PM, Demoitié M-A, Bayat B, Donner M-N, Bourguignon P, Stewart VA, Heppner DG, Garçon N, Cohen J. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 2008; 26:1072-82; PMID:18258343; http://dx.doi.org/10.1016/j.vaccine.2007.12.018
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009; 200:337-46; PMID:19569965; http://dx.doi.org/10.1086/600120
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Leroux-Roels I, Clement F, Ofori-Anyinam O, Lievens M, Jongert E, Moris P, Ballou WR, Cohen J. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: Randomized, double-blind study in malaria-naïve adults. Hum Vaccines Immunother 2014; 10:2211-9; http://dx.doi.org/10.4161/hv.29375
   PubMed Web of Science ®Google Scholar
• Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, Kai O, Jongert E, Lievens M, Leach A, et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PloS One 2011; 6:e25786; PMID:21998698; http://dx.doi.org/10.1371/journal.pone.0025786
   PubMed Web of Science ®Google Scholar
• Ansong D, Asante KP, Vekemans J, Owusu SK, Owusu R, Brobby NAW, Dosoo D, Osei-Akoto A, Osei-Kwakye K, Asafo-Adjei E, et al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PloS One 2011; 6:e18891; PMID:21556142; http://dx.doi.org/10.1371/journal.pone.0018891
   PubMed Web of Science ®Google Scholar
• Owusu-Agyei S, Ansong D, Asante K, Kwarteng Owusu S, Owusu R, Wireko Brobby NA, Dosoo D, Osei Akoto A, Osei-Kwakye K, Adjei EA, et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PloS One 2009; 4:e7302; PMID:19806184; http://dx.doi.org/10.1371/journal.pone.0007302
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois M-C, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521-32; PMID:19064627; http://dx.doi.org/10.1056/NEJMoa0807381
   PubMed Web of Science ®Google Scholar
• Garçon N, Slaoui M. New Adjuvants. In: Vaccines: preventing disease and protecting health. Washington, D.C.: Pan American Health Organization; 2003. page 263-72.
   Google Scholar
• Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, Slaoui M, Stanberry LR. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 2003; 187:542-9; PMID:12599070; http://dx.doi.org/10.1086/374002
   PubMed Web of Science ®Google Scholar
• Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 2005; 192:2117-23; PMID:16288376; http://dx.doi.org/10.1086/498247
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652-61; PMID:12444179; http://dx.doi.org/10.1056/NEJMoa011915
   PubMed Web of Science ®Google Scholar
• Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RLA, Ewell MG, Stokes-Riner A, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34-43; PMID:22216840; http://dx.doi.org/10.1056/NEJMoa1103151
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Clément F, Vandepapelière P, Fourneau M, Heineman TC, Dubin G. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. Hum Vaccines Immunother 2013; 9:1254-62; http://dx.doi.org/10.4161/hv.24043
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26:6266-73; PMID:18848855; http://dx.doi.org/10.1016/j.vaccine.2008.09.056
   PubMed Web of Science ®Google Scholar
• Tong NKC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, Vilella A, de Juanes JR, Arrazola P, Calbo-Torrecillas F, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68:2298-303; PMID:16221232; http://dx.doi.org/10.1111/j.1523-1755.2005.00689.x
   PubMed Web of Science ®Google Scholar
• Garçon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminium salt. In: Schijns V, O'Hagan D (eds) Immunopotentiators in Modern vaccines. London, UK: Academic Press; 2005. page 161-78.
   Google Scholar
• Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6:133-40; PMID:17408363; http://dx.doi.org/10.1586/14760584.6.2.133
   PubMed Web of Science ®Google Scholar
• Kong NCT, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas J-M, Vilella A, Calbo-Torrecillas F, López de Novales E, Srinivasa K, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008; 73:856-62; PMID:18160963; http://dx.doi.org/10.1038/sj.ki.5002725
   PubMed Web of Science ®Google Scholar
• Bosch FX, Muñoz N. The viral etiology of cervical cancer. Virus Res 2002; 89:183-90; PMID:12445658; http://dx.doi.org/10.1016/S0168-1702(02)00187-9
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin H-R, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008; 110:S1-10; PMID:18653222; http://dx.doi.org/10.1016/j.ygyno.2008.05.036
   PubMed Web of Science ®Google Scholar
• Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, Hurni WM, Joyce JG, Lehman ED, Markus HZ, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997; 176:1141-5; PMID:9359711; http://dx.doi.org/10.1086/514105
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49; PMID:16828940; http://dx.doi.org/10.1016/j.vaccine.2006.06.005
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55; PMID:16631880; http://dx.doi.org/10.1016/S0140-6736(06)68439-0
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65; PMID:15541448; http://dx.doi.org/10.1016/S0140-6736(04)17398-4
   PubMed Web of Science ®Google Scholar
• Roteli-Martins C, Naud P, De Borba P, Teixeira J, De Carvalho N, Zahaf T, Sanchez N, Geeraerts B, Descamps D. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccines Immunother 2012; 8:390-7; http://dx.doi.org/10.4161/hv.18865
   PubMed Web of Science ®Google Scholar
• De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-55; PMID:20643092; http://dx.doi.org/10.1016/j.vaccine.2010.07.007
   PubMed Web of Science ®Google Scholar
• Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RHM, Quek SC, da Silva DP, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014; 384:2213-27; PMID:25189358; http://dx.doi.org/10.1016/S0140-6736(14)60920-X
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http://dx.doi.org/10.1016/S1470-2045(11)70286-8
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KGJ, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110:2804-11; PMID:24736582; http://dx.doi.org/10.1038/bjc.2014.198
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin 2009; 5:705-19; PMID:19684472; http://dx.doi.org/10.4161/hv.5.10.9518
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Hildesheim A, Falk RT, Schiller JT, Lowy DR, Rodriguez AC, Pinto LA. Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol 2008; 15:60-4; PMID:18032596; http://dx.doi.org/10.1128/CVI.00118-07
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J. Effectiveness of preventive human papillomavirus vaccination. Int J STD AIDS 2003; 14:787-92; PMID:14678583; http://dx.doi.org/10.1258/095646203322556084
   PubMed Web of Science ®Google Scholar
• World Health Organisation. WHO activities in avian influenza and pandemic influenza preparedness. Available from: http://www.who.int/influenza/resources/documents/WHO_CDS_EPR_GIP_2006_6.pdf
   Google Scholar
• Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009; 9:1057-71; PMID:19555313; http://dx.doi.org/10.1517/14712590903066695
   PubMed Web of Science ®Google Scholar
• Baras B, Stittelaar KJ, Simon JH, Thoolen RJMM, Mossman SP, Pistoor FHM, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus ADME. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PloS One 2008; 3:e1401; http://dx.doi.org/10.1371/journal.pone.0001401
   PubMed Web of Science ®Google Scholar
• Baras B, Stittelaar KJ, Kuiken T, Jacob V, Bernhard R, Giannini S, de Waal L, van Amerongen G, Simon JH, Osterhaus ADME, et al. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 2011; 29:2092-9; PMID:21237275; http://dx.doi.org/10.1016/j.vaccine.2010.12.128
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster J-M, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9; PMID:17707753; http://dx.doi.org/10.1016/S0140-6736(07)61297-5
   PubMed Web of Science ®Google Scholar
• Díez-Domingo J, Garcés-Sanchez M, Baldó J-M, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, et al. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J 2010; 29:e35-46.
   PubMed Web of Science ®Google Scholar
• Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201:1644-53; PMID:20423222; http://dx.doi.org/10.1086/652701
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Horacek T, Knuf M, Damman H-G, Roman F, Dramé M, Gillard P, Jilg W. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90; PMID:19856521; http://dx.doi.org/10.1016/j.vaccine.2009.01.040
   PubMed Web of Science ®Google Scholar
• Press Announcements - FDA approves first adjuvanted vaccine for prevention of H5N1 avian influenza Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376444.htm
   Google Scholar
• World Health Organization. World now at the start of 2009 influenza pandemic. Available from: http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html
   Google Scholar
• Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster J-M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5; PMID:20034605; http://dx.doi.org/10.1016/j.vaccine.2009.12.014
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668-77; PMID:20687838; http://dx.doi.org/10.1086/655830
   PubMed Web of Science ®Google Scholar
• Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months–12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649; PMID:20508026; http://dx.doi.org/10.1136/bmj.c2649
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, Li P, Gillard P, Roman F. Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 2010; 6:888-93; PMID:20980795; http://dx.doi.org/10.4161/hv.6.11.12851
   PubMed Web of Science ®Google Scholar
• Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, Nilsen M, Mohn K, Jul-Larsen A, Smith I, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010; 29:266-73; PMID:21034828; http://dx.doi.org/10.1016/j.vaccine.2010.10.038
   PubMed Web of Science ®Google Scholar
• Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, Gillard P, Arístegui J. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine 2010; 28:5837-44; PMID:20600478; http://dx.doi.org/10.1016/j.vaccine.2010.06.065
   PubMed Web of Science ®Google Scholar
• Andrews N, Waight P, Yung C-F, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011; 203:32-9; PMID:21148494; http://dx.doi.org/10.1093/infdis/jiq014
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, Kwindt TL, Tang P, Charest H, Fonseca K, et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011; 342:c7297; PMID:21292718; http://dx.doi.org/10.1136/bmj.c7297
   PubMed Web of Science ®Google Scholar
• Van Buynder PG, Dhaliwal JK, Van Buynder JL, Couturier C, Minville-Leblanc M, Garceau R, Tremblay F-W. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respir Viruses 2010; 4:171-8; PMID:20629771; http://dx.doi.org/10.1111/j.1750-2659.2010.00146.x
   PubMed Web of Science ®Google Scholar
• Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MAP, Cruz-Valdez A, Litao S, et al. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J Infect Dis 2014; 210:545-57; PMID:24652494; http://dx.doi.org/10.1093/infdis/jiu173
   PubMed Web of Science ®Google Scholar
• Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns T. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Euro Surveill 2010; 15(18):19561.
   Google Scholar
• Valenciano M, Kissling E, Cohen J-M, Oroszi B, Barret A-S, Rizzo C, Nunes B, Pitigoi D, Larrauri Cámara A, Mosnier A, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 2011; 8:e1000388; PMID:21379316; http://dx.doi.org/10.1371/journal.pmed.1000388
   PubMed Web of Science ®Google Scholar
• Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol Assess 2010; 14:313-46; PMID:20630126
   PubMed Web of Science ®Google Scholar
• Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez-Vilar S, Silvestre-Silvestre E, Calvo-Mas C, Safont-Adsuara L, Ruiz-García M, Surveillance and Vaccine Evaluation Group during the autumn 2009 H1N1 pandemic wave in Castellón, Spain. Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. Vaccine 2010; 28:7460-7; http://dx.doi.org/10.1016/j.vaccine.2010.09.042
   PubMed Web of Science ®Google Scholar
• Hardelid P, Fleming DM, McMenamin J, Andrews N, Robertson C, SebastianPillai P, Ellis J, Carman W, Wreghitt T, Watson JM, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009–2010. Euro Surveill 2011; 13:16.
   Google Scholar
• Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013; 14:428-36; PMID:23598398; http://dx.doi.org/10.1038/ni.2588
   PubMed Web of Science ®Google Scholar
• Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35; PMID:18419349; http://dx.doi.org/10.1086/528696
   PubMed Web of Science ®Google Scholar
• Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 2012; 30:3126-35; PMID:22326899; http://dx.doi.org/10.1016/j.vaccine.2012.01.088
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206:1280-90; PMID:22872734; http://dx.doi.org/10.1093/infdis/jis497
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, et al. A Phase 3 trial of an adjuvanted herpes zoster subunit vaccine in older adults. NEJM 2015; 372:2087-96; PMID:25916341; http://dx.doi.org/10.1056/NEJMoa1501184
   PubMed Web of Science ®Google Scholar
• Brennan FR, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 2005; 23:3210-22; PMID:15837222; http://dx.doi.org/10.1016/j.vaccine.2004.11.072
   PubMed Web of Science ®Google Scholar
• Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8:235-47; PMID:18194079; http://dx.doi.org/10.1517/14712598.8.2.235
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 1950 2009; 183:6186-97; http://dx.doi.org/10.4049/jimmunol.0901474
   Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter DL, Kitchener HC, Castellsague X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1016/S0140-6736(07)60946-5
   PubMed Web of Science ®Google Scholar
• Angelo M-G, David MPP, Baril L, Struyf F, Zima J, Arellano F. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (Cervarix™): a pooled analysis of clinical trial data. Pharmacoepidemiol Drug Saf 2014; 23:466-79; PMID:24644063; http://dx.doi.org/10.1002/pds.3554
   PubMed Web of Science ®Google Scholar
• Angelo M, Zima J, Tavares F, Baril L, Arellano F. Post-licensure safety surveillance for AS04-adjuvanted Human Papillomavirus vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014; 23:456-65; PMID:24644078; http://dx.doi.org/10.1002/pds.3593
   PubMed Web of Science ®Google Scholar
• Sturkenboom MCJM. The narcolepsy-pandemic influenza story: can the truth ever be unraveled? Vaccine 2015; 33(Suppl 2):B6-13; PMID:26022571; http://dx.doi.org/10.1016/j.vaccine.2015.03.026
   PubMed Web of Science ®Google Scholar
• Vaarala O, Vuorela A, Partinen M, Baumann M, Freitag TL, Meri S, Saavalainen P, Jauhiainen M, Soliymani R, Kirjavainen T, et al. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk. PloS One 2014; 9:e114361; PMID:25501681; http://dx.doi.org/10.1371/journal.pone.0114361
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, Karle A, Rigat F, Rappuoli R, Narasimhan V, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med 2015; 7:294ra105; PMID:26136476; http://dx.doi.org/10.1126/scitranslmed.aab2354
   PubMed Web of Science ®Google Scholar
• Stassijns J, Bollaerts K, Baay M, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine 2016; 34:714-22; PMID:26740250; http://dx.doi.org/10.1016/j.vaccine.2015.12.024
   PubMed Web of Science ®Google Scholar
• Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272:50-3; PMID:8600536; http://dx.doi.org/10.1126/science.272.5258.50
   PubMed Web of Science ®Google Scholar
• Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003; 3:169-76; PMID:12563300; http://dx.doi.org/10.1038/nri1004
   PubMed Web of Science ®Google Scholar
• Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54(Pt 1):1-13; PMID:2700931; http://dx.doi.org/10.1101/SQB.1989.054.01.003
   PubMedGoogle Scholar
• The Nobel Prize in Physiology or Medicine 2011 [Internet]. [cited 2015 Mar 26]; Available from: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2011/
   Google Scholar
• Pulendran B, Oh JZ, Nakaya HI, Ravindran R, Kazmin DA. Immunity to viruses: learning from successful human vaccines. Immunol Rev 2013; 255:243-55; PMID:23947360; http://dx.doi.org/10.1111/imr.12099
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503; PMID:21029960; http://dx.doi.org/10.1016/j.immuni.2010.10.002
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-73; PMID:21256188; http://dx.doi.org/10.1016/j.vaccine.2011.01.011
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN, et al. Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells. J Immunol Baltim Md 1950 2014; 193:1920-30.
   Google Scholar
• Garcon N, Leroux-Roels G, Cheng W. Vaccine adjuvants. Perspectives in Vaccinology 2011; 1(1):89-113; http://dx.doi.org/10.1016/j.pervac.2011.05.004
   Google Scholar